The effects of topical erythropoietin on non-surgical treatment of periodontitis: a preliminary study

Hoori Aslroosta, Siamak Yaghobee, Solmaz Akbari, Negar Kanounisabet, Hoori Aslroosta, Siamak Yaghobee, Solmaz Akbari, Negar Kanounisabet

Abstract

Background: The purpose of periodontal treatments is to reduce inflammation, restore gingival health and clinical attachment level gain by controlling microbial plaque formation and other etiological factors. One of the drugs that has been tested in many areas and shown good anti-inflammatory properties is erythropoietin (EPO). We evaluated the effect of this drug on the improvement of periodontitis after the phase I treatment.

Methods: This study was conducted on 30 patients with stage III periodontitis who had at least two bilateral teeth with CAL of ≥ 5 mm and PPD ≥ 6 mm at ≥ 2 non-adjacent teeth and bleeding on probing. After oral hygiene instruction and scaling and root planning (SRP), EPO gel containing a solution of 4000 units was applied deeply in the test group and placebo gel was deeply administered in the control pockets (5 times, every other day). The clinical parameters of the plaque index (PI), gingival index (GI), clinical attachment level (CAL), probing depth (PD) and bleeding index (BI) were measured at baseline and after three months of follow up. The P-value was set at 0.05.

Results: All clinical variables improved after treatment in both groups. The BI and GI scores (which reflects the degree of gingival inflammation) showed statistically more reduction in test group. The CAL decreased from 5.1 ± 4.1 to 3.40 ± 2.71 mm; and 5.67 ± 4.32 to 4.33 ± 3.19 mm in test and control group, respectively (P < 0.00). After the treatment, there was a significant greater reduction in CAL and also PD values in test group (P < 0.01).

Conclusion: Local application of EPO gel in adjunct to SRP can improve clinical inflammation and CAL gain in periodontitis.

Trial registration: This study was registered at 2017-11-06 in IRCT. All procedures performed in this study were approved with ID number of IR.TUMS.DENTISTRY.REC.1396.3139 in Tehran University of medical science.

Keywords: Erythropoietin (EPO); Non-surgical periodontal treatment; Periodontitis.

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Consort flow chart
Fig. 2
Fig. 2
The amount of changes in periodontal parameters (CAL, PD) in each group during 3 months
Fig. 3
Fig. 3
The amount of changes in clinical periodontal parameters (PI, BI, GI) in each group during 3 months follow up

References

    1. Albandar JM. Underestimation of periodontitis in NHANES surveys. J Periodontol. 2011;82(3):337–341. doi: 10.1902/jop.2011.100638.
    1. Preshaw PM, Seymour RA, Heasman PA. Current concepts in periodontal pathogenesis. Dent Update. 2004;31(10):570–578. doi: 10.12968/denu.2004.31.10.570.
    1. Kantarci A, Van Dyke TE. Lipoxin signaling in neutrophils and their role in periodontal disease. Prostaglandins Leukot Essent Fatty Acids. 2005;73(3–4):289–299. doi: 10.1016/j.plefa.2005.05.019.
    1. Gemmell E, Marshall RI, Seymour GJ. Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease. Periodontol. 1997;14(1):112–143. doi: 10.1111/j.1600-0757.1997.tb00194.x.
    1. Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction. Periodontol. 1997;14(1):9–11. doi: 10.1111/j.1600-0757.1997.tb00189.x.
    1. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005;366(9499):1809–1820. doi: 10.1016/S0140-6736(05)67728-8.
    1. Higgs G, Vane J. Inhibition of cyclo-oxygenase and lipoxygenase. Br Med Bull. 1983;39(3):265–270. doi: 10.1093/oxfordjournals.bmb.a071831.
    1. Caton JG, Ciancio SG, Blieden TM, Bradshaw M, Crout RJ, Hefti AF, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol. 2000;71(4):521–532. doi: 10.1902/jop.2000.71.4.521.
    1. Wesley SJ. Microbial evaluation of a single subgingival irrigation with chlorhexidine and benzydamine in advanced periodontitis. World. 2014;5(1):37–41.
    1. Newman MG, Takei H, Klokkevold PR, Carranza FA. Carranza's clinical periodontology. Amsterdam: Elsevier Health Sciences; 2011.
    1. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med. 2008;264(5):405–432. doi: 10.1111/j.1365-2796.2008.02024.x.
    1. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol. 2007;78(3):183–205. doi: 10.1111/j.1600-0609.2007.00818.x.
    1. Strunk T, Härtel C, Temming P, Matzke N, Zimmer J, Schultz C. Erythropoietin inhibits cytokine production of neonatal and adult leukocytes. Acta Paediatr. 2008;97(1):16–20. doi: 10.1111/j.1651-2227.2007.00560.x.
    1. Sakanaka M, Wen T-C, Matsuda S, Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci. 1998;95(8):4635–4640. doi: 10.1073/pnas.95.8.4635.
    1. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci. 2002;99(16):10659–10664. doi: 10.1073/pnas.152321399.
    1. Santhanam AVR, d’Uscio LV, Peterson TE, Katusic ZS. Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides. 2008;29(8):1451–1455. doi: 10.1016/j.peptides.2008.03.016.
    1. Peterson T, Katusic ZS. EPO tecting the endothelium. Br J Pharmacol. 2007;150(7):823–825. doi: 10.1038/sj.bjp.0707162.
    1. Hamed S, Bennett CL, Demiot C, Ullmann Y, Teot L, Desmoulière A. Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with diabetes mellitus. Wound Repair Regen. 2014;22(1):23–33. doi: 10.1111/wrr.12135.
    1. Bader A, Lorenz K, Richter A, Scheffler K, Kern L, Ebert S, et al. Interactive role of trauma cytokines and erythropoietin and their therapeutic potential for acute and chronic wounds. Rejuvenation Res. 2011;14(1):57–66. doi: 10.1089/rej.2010.1050.
    1. Giri P, Ebert S, Braumann U-D, Kremer M, Giri S, Machens H-G, et al. Skin regeneration in deep second-degree scald injuries either by infusion pumping or topical application of recombinant human erythropoietin gel. Drug Des Dev Ther. 2015;9:2565. doi: 10.2147/DDDT.S79425.
    1. Geary MB, Li H, Zingman A, Ketz J, Zuscik M, De Mesy Bentley KL, et al. Erythropoietin accelerates functional recovery after moderate sciatic nerve crush injury. Muscle Nerve. 2017;56(1):143–151. doi: 10.1002/mus.25459.
    1. Yaghobee S, Rouzmeh N, Aslroosta H, Mahmoodi S, Khorsand A, Kharrazifard MJ. Effect of topical erythropoietin (EPO) on palatal wound healing subsequent to free gingival grafting (FGG). Brazilian Oral Research. 2018;32.
    1. Brines M. From the cover: erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci. 97(19).
    1. de Lucas CA, Bond WS, Rex TS. Safety and angiogenic effects of systemic gene delivery of a modified erythropoietin. Gene Ther. 2015;22(5):365–373. doi: 10.1038/gt.2015.12.
    1. Carlson RV, Boyd KM, Webb DJ. The revision of the declaration of Helsinki: past, present and future. Br J Clin Pharmacol. 2004;57(6):695–713. doi: 10.1111/j.1365-2125.2004.02103.x.
    1. Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, et al. Periodontitis: consensus report of workgroup 2 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. J Periodontol. 2018;89:S173–S182. doi: 10.1002/JPER.17-0721.
    1. Silness J, Löe H. Periodontal disease in pregnancy II Correlation between oral hygiene and periodontal condition. Acta Odontol Scand. 1964;22(1):121–135. doi: 10.3109/00016356408993968.
    1. Ramfjord SP. Indices for prevalence and incidence of periodontal disease. 1959.
    1. Newbrun E. Indices to measure gingival bleeding. J Periodontol. 1996;67(6):555–561. doi: 10.1902/jop.1996.67.6.555.
    1. Hefti AF, Preshaw PM. Examiner alignment and assessment in clinical periodontal research. Periodontol. 2012;59(1):41–60. doi: 10.1111/j.1600-0757.2011.00436.x.
    1. Golub LM, Lee HM. Periodontal therapeutics: current host-modulation agents and future directions. Periodontol. 2020;82(1):186–204. doi: 10.1111/prd.12315.
    1. Elkhouli A. The efficacy of host response modulation therapy (omega-3 plus low-dose aspirin) as an adjunctive treatment of chronic periodontitis (clinical and biochemical study) J Periodontal Res. 2011;46(2):261–268. doi: 10.1111/j.1600-0765.2010.01336.x.
    1. Özden FO, Sakallioğlu EE, Demir E, Bilgici B, Tunçel ÖK, Gökosmanoğlu F, et al. Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-κB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis. J Oral Sci. 2017;59(1):147–155. doi: 10.2334/josnusd.16-0241.
    1. Cervellini I, Sacre S, Ghezzi P, Mengozzi M. Erythropoietin does not affect TNF and IL-6 production directly. J Biol Regul Homeost Agents. 2013;27(1):189–196.
    1. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141(1):14–31. doi: 10.1111/j.1365-2141.2008.07014.x.
    1. Lombardero M, Kovacs K, Scheithauer BW. Erythropoietin: a hormone with multiple functions. Pathobiology. 2011;78(1):41–53. doi: 10.1159/000322975.
    1. Rölfing JHD, Bendtsen M, Jensen J, Stiehler M, Foldager CB, Hellfritzsch MB, et al. Erythropoietin augments bone formation in a rabbit posterolateral spinal fusion model. J Orthop Res. 2012;30(7):1083–1088. doi: 10.1002/jor.22027.
    1. Wan L, Zhang F, He Q, Tsang WP, Lu L, Li Q, et al. EPO promotes bone repair through enhanced cartilaginous callus formation and angiogenesis. PLoS ONE. 2014;9(7):e102010. doi: 10.1371/journal.pone.0102010.
    1. Klontzas E, Kenanidis I, MacFarlane J, Michail R, Potoupnis TE, Heliotis M, et al. Investigational drugs for fracture healing: preclinical & clinical data. Expert Opin Investig Drugs. 2016;25(5):585–596. doi: 10.1517/13543784.2016.1161757.
    1. Galeano M, Altavilla D, Bitto A, Minutoli L, Calò M, Cascio PL, et al. Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds. Crit Care Med. 2006;34(4):1139–1146. doi: 10.1097/.
    1. Fayyazzadeh E, Ahmadi SH, Rabani S, Boroumand MA, Salavati A, Sotoudeh AM. A comparative study of recombinant human basic fibroblast growth factor (bFGF) and erythropoietin (EPO) in prevention of skin flap ischemic necrosis in rats. 2012.
    1. Chen F-M, Zhang J, Zhang M, An Y, Chen F, Wu Z-F. A review on endogenous regenerative technology in periodontal regenerative medicine. Biomaterials. 2010;31(31):7892–7927. doi: 10.1016/j.biomaterials.2010.07.019.
    1. Wang L, Wu F, Song Y, Duan Y, Jin Z. Erythropoietin induces the osteogenesis of periodontal mesenchymal stem cells from healthy and periodontitis sources via activation of the p38 MAPK pathway. Int J Mol Med. 2018;41(2):829–835.
    1. Kim J, Jung Y, Sun H, Joseph J, Mishra A, Shiozawa Y, et al. Erythropoietin mediated bone formation is regulated by mTOR signaling. J Cell Biochem. 2012;113(1):220–228. doi: 10.1002/jcb.23347.
    1. Hamed S, Ullmann Y, Masoud M, Hellou E, Khamaysi Z, Teot L. Topical erythropoietin promotes wound repair in diabetic rats. J Investig Dermatol. 2010;130(1):287–294. doi: 10.1038/jid.2009.219.
    1. Pradeep A, Karvekar S, Nagpal K, Patnaik K, Guruprasad C, Kumaraswamy K. Efficacy of locally delivered 1.2% rosuvastatin gel to non-surgical treatment of patients with chronic periodontitis: a randomized, placebo-controlled clinical trial. J Periodontol. 2015;86(6):738–745. doi: 10.1902/jop.2015.140631.
    1. Garnick J, Keagle J, Searle J, King G, Thompson W. Gingival resistance to probing forces: II. The effect of inflammation and pressure on probe displacement in beagle dog gingivitis. J Periodontol. 1989;60(9):498–505. doi: 10.1902/jop.1989.60.9.498.
    1. Omlor GW, Kleinschmidt K, Gantz S, Speicher A, Guehring T, Richter W. Increased bone formation in a rabbit long-bone defect model after single local and single systemic application of erythropoietin. Acta Orthop. 2016;87(4):425–431. doi: 10.1080/17453674.2016.1198200.
    1. Emingil G, Gürkan A, Tervahartiala T, Hernandez M, Özgül S, Sorsa T, et al. Adjunctive effects of a sub-antimicrobial dose of doxycycline on clinical parameters and potential biomarkers of periodontal tissue catabolism. Dentistry J. 2019;7(1):9. doi: 10.3390/dj7010009.
    1. Preshaw PM, Hefti AF, Jepsen S, Etienne D, Walker C, Bradshaw MH. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis: a review. J Clin Periodontol. 2004;31(9):697–707. doi: 10.1111/j.1600-051X.2004.00558.x.
    1. Preshaw PM. Host modulation therapy with anti-inflammatory agents. Periodontol. 2018;76(1):131–149. doi: 10.1111/prd.12148.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever